Human T-ALL Xenografts.

Area of Science:

• Oncology
• Hematology
• Preclinical Research

Background:

• Intense chemotherapy improves survival in T cell acute lymphoblastic leukemia (T-ALL), particularly in children.
• T-ALL treatment faces challenges due to severe drug side effects and significant relapse rates.
• Effective preclinical models are crucial for developing novel T-ALL therapies.

Purpose of the Study:

• To describe the laboratory workflow for establishing and utilizing patient-derived xenografts (PDX) in T-ALL research.
• To provide a comprehensive guide for preclinical studies investigating new therapeutic strategies for T-ALL.
• To facilitate the transition of promising T-ALL therapies from in vitro validation to clinical trials.

Main Methods:

• Processing of primary human T-ALL patient samples.
• Genetic modification of leukemic cells using lentiviral transduction.
• Inoculation, disease monitoring, and treatment administration in mouse models, followed by organ examination.

Main Results:

• Detailed description of the PDX assay workflow from sample acquisition to treatment evaluation.
• Demonstration of PDX models' utility in recapitulating human T-ALL biology.
• Establishment of a reproducible methodology for preclinical T-ALL therapy testing.

Conclusions:

• Patient-derived xenografts (PDX) are valuable preclinical models for T-ALL research.
• The described workflow enables comprehensive evaluation of novel therapeutic strategies.
• PDX models are essential for advancing T-ALL treatment development toward clinical application.